Answers are grounded in this paper and cite their sources.
AOS3 ameliorates gouty arthritis via activating Nrf2-dependent antioxidant signaling, resulting in suppression of ROS-mediated NLRP3 inflammasome activation and TRPV1 enhancement. AOS3 may be novel therapeutics for gouty arthritis.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: